

D. OVERALL PARTICIPANTS

D.1 WHAT INDIVIDUALS HAVE WORKED ON THE PROJECT?

Commons ID	S/K	Name	SSN	DOB	Degree(s)	Role	Cal	Aca	Sum	Foreign Org	Country	SS
MARYMH	Y	Horowitz, Mary,	4808	07/1954	MS,MD	PD/PI	2	0	0			NA
	N	Carreras, Jeanette,	3701	09/1980	MS	Statistician	6	0	0			NA
	N	Korman, Sandra,	4668	10/0071	MS	Statistician	1	0	0			NA
	N	Perez, Waleska,	9977	12/1970	MS	Statistician	6	0	0			NA
HARIPN	Y	Hari, Parameswaran,	6532	03/1968	MD,MS	Co-Investigator	1	0	0			NA
JLERADE	Y	Le-Rademacher, Jennifer,	2344	07/1975	PhD	Co-Investigator	1	0	0			NA
KWOOAHN	Y	Ahn, Kwang Woo,	0117	12/1977	PhD	Co-Investigator	3	0	0			NA
MARYEAPEN	Y	EAPEN, MARY,	0828	03/1962	MS,MBBS	Co-Investigator	4	0	0			NA
MEIJIE	Y	Zhang, Mei-Jie,	7986	07/1948	PhD	Co-Investigator	7	0	0			NA
MMARTENS1	N	Martens, Michael,	5756	04/1981	MS	Graduate Student (research assistant)	12	0	0			NA
PASQUINIM	Y	Pasquini, Marcelo,	2693	01/1973	MD,MS	Co-Investigator	1	0	0			NA
SABER30	Y	Saber, Wael,	9866	10/1972	MD,MB	Co-Investigator	1	0	0			NA
	N	Burkart, Jeanne,	2567	10/0082		Business System Analyst Associate	12	0	0			NA
	N	Kulkarni, Swati,	9953	02/1979		Data Analyst	4	0	0			NA
	N	Meiers, Sharon,	3706	01/1959		Clinical Research Manager	12	0	0			NA
	N	Prentice, Amy,	2414	06/1979		Data Analyst	6	0	0			NA
	N	Simaytis, Maggie,	5919	05/0081		Program Coordinator	12	0	0			NA
JEGILLIS	N	Gillis-Smith, Jessica,	3602	03/1983		Medical Writer	2	0	0			NA
LORENZSA	N	Lorenz, Sue,	4410	10/1959	BS	Business Manager	1	0	0			NA

STEINERTP	N	Steinert, Patricia,	6069	11/1960	PhD	Research Administrator	2	0	0			NA
	Y	Brazauskas, Ruta,	3924	11/1969	PhD	Co-Investigator	5	0	0			NA

Glossary of acronyms: S/K - Senior/Key DOB - Date of Birth Cal - Person Months (Calendar) Aca - Person Months (Academic) Sum - Person Months (Summer)	Foreign Org - Foreign Organization Affiliation SS - Supplement Support RE - Reentry Supplement DI - Diversity Supplement OT - Other NA - Not Applicable
---	--

D.2 PERSONNEL UPDATES

D.2.a Level of Effort

Will there be, in the next budget period, either (1) a reduction of 25% or more in the level of effort from what was approved by the agency for the PD/PI(s) or other senior/key personnel designated in the Notice of Award, or (2) a reduction in the level of effort below the minimum amount of effort required by the Notice of Award?

No

D.2.b New Senior/Key Personnel

Are there, or will there be, new senior/key personnel?

No

NOTHING TO REPORT

D.2.c Changes in Other Support

Has there been a change in the active other support of senior/key personnel since the last reporting period?

Yes

File uploaded: U24CA076518-18_OtherSupport_Combined.pdf

D.2.d New Other Significant Contributors

Are there, or will there be, new other significant contributors?

No

NOTHING TO REPORT

D.2.e Multi-PI (MPI) Leadership Plan

Will there be a change in the MPI Leadership Plan for the next budget period?

NA

NOTHING TO REPORT

資料説明-5：CIBMTR の全グラント一覧

CIBMTR 研究費の内、NIH からの研究費が占める割合を示す資料である。

Department of Medicine
Center for International Blood and Marrow Transplant Research
Funding Summary of Active and Completed Grants/Contracts in the Last 3 Years

PI	GrantTitle	Sponsor	Grant#	Current MCW Project#	StartDate	EndDate	Direct Funds Total	Indirect Funds TOTAL	Grand Total Funds	Comments
Non-Federal Funding										
Eapen, M.	LLS Career Development Award	Leukemia & Lymphoma Society		2207498	7/1/2009	6/30/2014	\$ 486,980	\$ 24,349	\$ 511,329	
Eapen, M.	Six Month Follow Up Study of ECP vs Standard Therapy A Randomized, Prospective, Double Blinded, Placebo-controlled, Phase III Study of US-ATG-Fresenius (US-ATG-F)	Therakos		3306673	8/20/2014	12/19/2015	\$ 142,000	\$ 35,500	\$ 177,500	
Horowitz, M.	Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid and Acute Lymphoid Leukemia Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors	Fresenius Biotech North America, Inc.	FO706598	3305433	9/15/2011	9/14/2014	\$ 68,251	\$ 17,063	\$ 85,314	
Horowitz, M.	Long Term Complications after Stem Cell Transplantation for Multiple Myeloma	Celgene Corporation	MM10-01	3305696	1/1/2012	6/30/2013	\$ 49,600	\$ 12,400	\$ 62,000	
Horowitz, M.	Services Agreement #204773: CIBMTR ViaCord Project	National Marrow Donor Program	204773	2207988	3/9/2012	3/8/2014	\$ 85,348	\$ 21,337	\$ 106,685	
Horowitz, M.	Survival Rates in ADA-SCID Patients	GlaxoSmithKline		3306097	4/29/2013	4/28/2015	\$ 25,000	\$ 6,250	\$ 31,250	
Horowitz, M.	Services Agreement #201193: Celgene Support for BMT CTN #0702	National Marrow Donor Program	201193	2207697	8/1/2011	12/31/2013	\$ 55,761	\$ 29,553	\$ 85,314	
Horowitz, M.	Services Agreement #201089: 09-MRD Study	National Marrow Donor Program	201089	2208240	10/1/2010	9/30/2015	\$ 76,858	\$ -	\$ 76,858	
Horowitz, M.	Gentium VOD: Defibrotide for the Treatment of HCT Patients with Severe Hepatic Veno-Occlusive Disease (VOD)	Gentium SpA		3306163	6/1/2013	5/31/2014	\$ 81,500	\$ 20,375	\$ 101,875	
Horowitz, M.	Haplo UCB vs DUCB Comparison	Miltenyi Biotec		3306162	7/25/2013	8/24/2014	\$ 34,000	\$ 8,500	\$ 42,500	
Horowitz, M.	Novartis Task Order No. 2 - CIBMTR Center Volumes Dataset	Novartis		3306683	7/21/2014	7/20/2015	\$ 4,000	\$ 1,000	\$ 5,000	
Horowitz, M.	Novartis AML FLT3	Novartis		3306594	5/7/2014	5/6/2015	\$ 20,000	\$ 5,000	\$ 25,000	
Pasquini, M.	Comparison of conditioning regimens using intravenous busulfan versus total body irradiation for allogeneic hematopoietic stem cell transplantation in hematologic malignancies	Otsuka America Pharmaceutical, Inc.	OPDC Legal DB# 09160617	3304489	3/1/2009	6/30/2015	\$ 2,860,071	\$ 1,001,025	\$ 3,861,096	
Pasquini, M.	Stem Cell Transplant Controls with Non-Hodgkin and Hodgkin's Lymphoma using BEAM regimen for OPDC Protocol 273-08-201	Otsuka America Pharmaceutical, Inc.	OPDC Legal DB#1085194	3305366	3/1/2011	12/31/2013	\$ 200,292	\$ 50,073	\$ 250,365	
Pasquini, M.	PD-1/PD-L1 Expression in Myeloma	AHW (Cancer Center)	5520258	5520258	1/1/2013	12/31/2013	\$ 15,000	\$ -	\$ 15,000	
Saber, W.	A Prospective Cohort Study comparing outcomes of patients receiving hematopoietic stem cell transplantation for hematologic malignancies with and without Kevipance	Biovitrum AB	20050187	3303592	7/1/2006	12/31/2019	\$ 9,305,513	\$ 3,256,930	\$ 12,562,443	
Saber, W.	Kevipance Use in a Pediatric Population	Sobi Inc.	SC01-13	3306326	10/1/2013	12/31/2014	\$ 122,500	\$ 30,625	\$ 153,125	
							\$ 13,632,674	\$ 4,519,979	\$ 18,152,653	
Federal Funding										
Horowitz, M.	A Data Resource for Analyzing Blood and Marrow Transplants	NIH-NCI	2 U24 CA076518	2208427	3/1/2013	2/28/2018	\$ 15,137,342	\$ 2,962,658	\$ 18,100,000	
Horowitz, M.	A Data Resource for Analyzing Blood and Marrow Transplants	NIH-NCI	2 U24 CA076518	2207344 (closed)	3/1/2008	2/28/2013	\$ 12,881,026	\$ 2,618,973	\$ 15,499,999	
Horowitz, M.	A Data Resource for Analyzing Blood and Marrow Transplants	NIH-NCI	2 U24 CA076518-12S1 (ARRA Supplement)	2205887	8/1/2009	7/31/2011	\$ 384,061	\$ 175,646	\$ 559,707	
Horowitz, M.	BMT clinical research network data coordinating center	NIH-NHLBI	5 U10 HL069294	2208565, 2208566	7/1/2011	6/30/2017	\$ 42,609,749	\$ 2,183,995	\$ 44,793,744	
Horowitz, M.	BMT clinical research network data coordinating center	NIH-NHLBI	5 U01 HL069294	Closed	8/1/2006	7/31/2011	\$ 45,301,817	\$ 1,041,696	\$ 46,343,513	
Horowitz, M.	Easy-to-read Informed Consent for HCT Clinical Trials	NIH-NHLBI	5 U01 HL0692912S1 (Supplement)	2208237	9/1/2012	8/31/2015	\$ 354,517	\$ 65,532	\$ 420,049	
Horowitz, M.	Subcontract for BMT CTN Protocols 0803/0903	Westat, Inc.	8339-504	2208194	8/1/2011	8/31/2015	\$ 2,618,745	\$ 1,387,935	\$ 4,006,680	Subcontract
Horowitz, M.	Data Collection on the Efficacy of PCP Prophylaxis Agents (TMP/SMX) in BMT Patients	NIH-NCI	HHSN26120090592P	Closed	9/16/2009	9/15/2011	\$ 44,802	\$ -	\$ 44,802	
Horowitz, M.	RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality of Life (subaward - PI: Pulsipher)	NIH	1 R01 HL085707	2207575	12/1/2008	5/31/2014	\$ 77,431	\$ 39,877	\$ 117,308	Subcontract
Pasquini, M.	Prognostic Immunophenotyping in Multiple Myeloma Treatment with Novel Agents (PRIMeR)	NIH-NHLBI	1 R01 HL107213	2206964	6/1/2011	3/31/2015	\$ 1,287,223	\$ 206,717	\$ 1,493,940	
Pasquini, M. (Fonseca, R - PI)	Chromosomal Abnormalities in Myeloma as Detected by FISH	NIH	2 R01 CA083724	2207925	3/1/2009	1/31/2014	\$ 68,070	\$ 35,056	\$ 103,126	Subcontract
Pasquini, M. (Hahn, T - PI)	Genetic Susceptibility to Unrelated Donor Stem Cell Transplant-related Mortality	NIH-NHLBI	1 R01 HL102278-A1	2207973	7/5/2010	6/30/2014	\$ 54,313	\$ 28,243	\$ 82,556	Subcontract
Rizzo, J.D.	Stem cell therapeutic outcomes database	HRSA	HHS H250201200016C	2207725	9/27/2012	9/26/2017	\$ 16,576,695	\$ 3,440,231	\$ 20,016,926	
Rizzo, J. D.	Stem cell therapeutic outcomes database	HRSA	HHS H234200637015C	2204366 (closed)	9/27/2006	9/26/2012	\$ 17,282,807	\$ 4,379,071	\$ 21,661,878	
							\$ 154,678,998	\$ 18,565,630	\$ 173,244,228	
Total Funding							\$ 168,311,272	\$ 23,085,609	\$ 191,396,881	

考察

巻頭言でも述べた如く CIBMTR は我が国の JDCHCT と造血細胞移植領域 10 以上の研究班を合体させた様な機構であり、米国でも競合相手の無い特殊な組織である。即ちデータ収集からそれを用いた研究の実施までを広範囲に行っている。それらを支える研究費の多くが NIH からのものであるが、競合者が少ないので、申請以降の作業はかなりの特典に恵まれているように思われた。配分研究費の額が、桁が違うことはここでは言及しないが、研究者、職員の給与の一部が必ずどの Grant にも含まれていることは、周知のこととはいえ今一度確認しておきたい（これも高額である要因の一つである）。申請書、承諾書、中間報告書等の内容は良く言えば充実している、悪く言えば膨大すぎる、と考えるが、いったん承認されれば 5 年間の研究費が保証されるのは魅力であろう（無論これも研究毎によって異なるが）。この調査を踏まえて我が国の平成 27 年度以降の新しい仕組みを考える時、現在走っている 10 以上の研究班と JDCHCT が、合体は出来ないがそれに近い効果を得るようにすることが一つの方策としてあると思う。現在造血細胞移植関連研究班は年 2 回合同班会議を開いており、これは優れた仕組みであると思うが、これに加えて別途班長会議のようなものを、JDCHCT を交えて開き、データの使い方及び研究班運営上の相互情報交換を行うことにより、造血細胞移植領域のより有効な発展を実現できるのではないかと考える。

平成 26 年度
免疫アレルギー疾患等実用化研究事業 (移植医療分野) に関連する
研究開発管理の実施・評価に関する研究

**米国に於いて NIH から研究費を支給されている一主要研究
機関－CIBMTR－の実情に関する調査研究**

The status of a major institute who receives NIH grants in the US

発行／2015 年 2 月

発行者／造血幹細胞移植分野プログラムディレクター

小 寺 良 尚

印刷所／相羽印刷株式会社

